Clinical Trials Directory
Recruiting
Conditions
Sponsors
Search
About
Trials
/
Sponsors
/ Mirror Biologics, Inc.
Mirror Biologics, Inc.
Industry · 15 registered clinical trials.
Status
Trial
Phase
Started
Withdrawn
Combined AlloStim+Anti-PD-L1 in 4L MSS Metastatic Colorectal Cancer
Metastatic Colorectal Cancer
Phase 2
2026-11-01
Suspended
Immunotherapy for Advanced Liver Cancer
Hepatocellular Carcinoma
Phase 2 / Phase 3
2023-08-01
Completed
Universal Anti-Viral Vaccine for Healthy Elderly Adults
Virus Diseases, Pneumonia, COVID-19 Respiratory Infection
Phase 1 / Phase 2
2021-07-12
Completed
Immunotherapy for Third Line Metastatic Colorectal Cancer
Metastatic Colorectal Cancer
Phase 2
2021-07-12
Withdrawn
AlloStim® In-Situ Vaccine in Pre-Treated Metastatic Colorectal Cancer
Metastatic Colorectal Cancer
Phase 2 / Phase 3
2017-12-01
Withdrawn
Study Comparing AlloVax™ to Chemotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head & Neck
Squamous Cell Carcinoma Head and Neck
Phase 2
2016-12-01
Completed
AlloStim® Immunotherapy Dosing Alone or in Combination With Cryoablation in Metastatic Colorectal Cancer
Colorectal Cancer Metastatic
Phase 2
2016-09-01
Completed
An Individualized Anti-Cancer Vaccine in Advanced Hepatocellular Carcinoma Subjects
Advanced Adult Hepatocellular Carcinoma
Phase 2
2016-07-01
Completed
Safety and Tolerability Study of AlloVax(TM) in Patients With Metastatic or Recurrent Cancer of the Head and N
Cancer of Head and Neck, Squamous Cell Carcinoma of the Head and Neck
Phase 2
2016-01-01
Withdrawn
In-Situ Therapeutic Cancer Vaccine for Refractory Liver Cancer
Hepatocellular Carcinoma
Phase 1 / Phase 2
2014-11-01
Withdrawn
Increased Frequency of AlloStim(TM) Dosing in Combination With Cryoablation in Metastatic Breast Cancer Patien
Metastatic Breast Cancer
Phase 1 / Phase 2
2014-03-01
Withdrawn
An Individualized Anti-Cancer Vaccine Study in Patients With HCC
Hepatocellular Carcinoma
Phase 1 / Phase 2
2013-12-01
Completed
A Phase I/II Study of Mis-Matched Immune Cells (AlloStim) in Patients With Advanced Hematological Malignancy
Hematological Malignancy, Leukemia, Lymphoma
Phase 1 / Phase 2
2010-12-01
Terminated
Bioengineered Allogeneic Immune Cells (AlloStim) Not Requiring HLA Donor Match for Blood Cancers
Advanced or Refractory Leukemia, Lymphoma, Multiple Myeloma
Phase 1 / Phase 2
2010-01-01
Completed
In-Situ Therapeutic Cancer Vaccine for Metastatic Cancer Combining AlloStim With Tumor Cryoablation
Metastatic Cancer
Phase 1 / Phase 2
2009-08-01